News | March 12, 2025
Nectar Lifesciences receives 7 observations from EDQM for API facility
The European regulator will conduct a re-inspection of the facility to verify the compliance
The European regulator will conduct a re-inspection of the facility to verify the compliance
Standalone profit from operations for Q4-2024 were Rs. 108 crore
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
the inspection conducted from January 27 to January 31, 2025
This rating reflects Lupin's leadership in environmental transparency and performance
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent
Wockhardt also saw its revenue from operations increased 3% to Rs. 721 crore during Q3 FY25
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
Cancer cases in India estimated to reach 1.57 million in 2025
Subscribe To Our Newsletter & Stay Updated
